Ken Griffin Verona Pharma PLC Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 94,100 shares of VRNA stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,100
Previous 1,396,644
93.26%
Holding current value
$10.1 Million
Previous $132 Million
92.4%
% of portfolio
0.0%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding VRNA
# of Institutions
275Shares Held
77.1MCall Options Held
686KPut Options Held
442K-
Pentwater Capital Management LP Naples, FL5.3MShares$567 Million3.55% of portfolio
-
Hbk Investments L P Dallas, TX4.26MShares$456 Million6.29% of portfolio
-
Fil LTD Hamilton, D03.49MShares$373 Million0.32% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million15.27% of portfolio
-
Davidson Kempner Capital Management LP New York, NY3.27MShares$350 Million10.89% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...